drugset / Trial / NCT07056842
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite VCT289. Cohort 1 will assess the impact of rifampin (600 mg once daily) on VCT220 (160 mg single dose). Cohort 2 will assess the impact of itraconazole (200 mg once daily) on VCT220 (40 mg single dose). A total of 32 healthy subjects will be enrolled, 16 in each cohort.
Timeline
- Start
- 2025-07-20
- Primary completion
- 2025-08-11
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |
| Subject | VCT220 | Small molecule | 40 mg | Oral |
| Subject | VCT220 | Small molecule | 160 mg | Oral |